who developed it?
Maurice Hilleman
Hepatitis B vaccine
The American microbiologist/vaccinologist Maurice Hilleman at Merck used three treatments (pepsin, urea and formaldehyde) of blood serum together with rigorous filtration to yield a product that could be used as a safe vaccine.
hepatitis b is most commonly transmitted via which of the following routes Exposure to infectious blood or body fluids containing blood;  sexual contact, blood transfusions and transfusion with other human blood products, re-use of contaminated needles and syringes, and vertical transmission from mother to child (MTCT) during childbirth. what are the early indications? Many people have no symptoms during the initial infection. In acute infection, some may develop a rapid onset of sickness with vomiting, yellowish skin, tiredness, dark urine and abdominal pain.  It may take 30 to 180 days for symptoms to begin. who discovered the virus? Baruch Blumberg is there a cure? Although none of the available medications can clear the infection, they can stop the virus from replicating, thus minimizing liver damage. can the virus recur in a person once cured? Yes - The virus DNA remains in the body after infection, and in some people, including those that do not have detectable HBsAg, the disease recurs. Although rare, reactivation is seen most often following alcohol or drug use, or in people with impaired immunity are there any boosters taken to prevent it? Yes - The hepatitis B vaccine who can be given this vaccine? Babies, children, pregnant women what is the name of this vaccine? hepatitis B vaccine
wiki:10545511
Hepatitis B vaccine [SEP] History
In 1963, the American physician/geneticist Baruch Blumberg discovered what he called the "Australia Antigen" (now called HBsAg) in the serum of an Australian Aboriginal person. In 1968, this protein was found to be part of the virus that causes "serum hepatitis" (hepatitis B) by virologist Alfred Prince. The American microbiologist/vaccinologist Maurice Hilleman at Merck used three treatments (pepsin, urea and formaldehyde) of blood serum together with rigorous filtration to yield a product that could be used as a safe vaccine. Hilleman hypothesized that he could make an HBV vaccine by injecting patients with hepatitis B surface protein. In theory, this would be very safe, as these excess surface proteins lacked infectious viral DNA.